OTHER INFORMATION
−Removed: During the quarter ended September 30, 2024, there was no information required to be disclosed in a report on Form 8-K which was not
−Removed: disclosed in a report on Form 8-K.
−Removed: During the quarter ended September 30, 2024, there were no material changes to the procedures by which stockholders may recommend nominees
+Added: During the quarter ended March 31, 2025, there was no information required to be disclosed in a report on Form 8-K which was not disclosed
+Added: in a report on Form 8-K.
+Added: During the quarter ended March 31, 2025, there were no material changes to the procedures by which stockholders may recommend nominees
to our board of directors.
−Removed: (c) During the quarter ended September 30, 2024, no officer or director
−Removed: adopted or terminated (1) a plan, contract, or set of instructions intended to by covered by the 10b5-1 affirmative defense or (2) a written
−Removed: trading arrangement as defined in Item 408(c) of Regulation S-K.
−Removed: Agreement and Plan of Merger, dated July 25, 2024, by and among the Company, MEDS Merger Sub I, Inc., MEDS Merger Sub II, LLC, and Scienture, Inc.
−Removed: (incorporated by reference to Exhibit 2.1 of the Company’s Form 8-K filed on July 31, 2024).
−Removed: Second Amended and Restated Certificate of Incorporation of the Company, as amended through September 20, 2024.
−Removed: Amended and Restated Bylaws of the Company, as amended through March 24, 2022.
+Added: During the quarter ended March 31, 2025, no officer or director adopted or terminated (1) a plan, contract, or set of instructions intended
+Added: to by covered by the 10b5-1 affirmative defense or (2) a written trading arrangement as defined in Item 408(c) of Regulation S-K.
+Added: Amended and Restated Certificate of Incorporation of the Company, as amended through September 20, 2024 (incorporated by reference
+Added: to Exhibit 3.1 of the Company’s Form 10-K filed on March 26, 2025).
+Added: Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (1-for-6 Reverse Stock Split of Common Stock) filed with the Delaware Secretary of State on February 12, 2020, and effective February 13, 2020 (incorporated by reference to Exhibit 3.3 of the Company’s Form 10-K filed on March 26, 2025).
+Added: Certificate of Amendment of Certificate of Incorporation (changing name TRxADE HEALTH, INC.) (incorporated by reference to Exhibit 3.4 of the Company’s Form 10-K filed on March 26, 2025).
+Added: Form of Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.5 of the Company’s Form 10-K filed on March 26, 2025).
+Added: Certificate of Amendment of Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.6 of the Company’s Form 10-K filed on March 26, 2025).
+Added: and Restated Bylaws of the Company, as amended through March 24, 2022 (incorporated by reference to Exhibit 3.10 of the
+Added: Company’s Form 10-K filed on March 26, 2025).
Certificate of Designation of Series B Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed on June 26, 2023).
+Added: Certificate of Designation of Preferences, Rights and Limitations of Series C Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed on October 11, 2023).
Certificate of Designation of Preference, Rights and Limitations of Series X Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed on July 31, 2024).
−Removed: Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.1 of the Company’s Form 8-K filed on July 31, 2024).
−Removed: Consulting Agreement, dated July 25, 2024, by and between the Company and Surendra K.
−Removed: Ajjarapu (incorporated by reference to Exhibit 10.2 of the Company’s Form 8-K filed on July 31, 2024).
−Removed: Consulting Agreement, dated July 25, 2024, by and between the Company and Prashant Patel (incorporated by reference to Exhibit 10.3 of the Company’s Form 8-K filed on July 31, 2024).
−Removed: Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.4 of the Company’s Form 8-K filed on July 31, 2024).
−Removed: Assignment and Assumption of Membership Interests – Integra Pharma Solutions, LLC, dated October 4, 2024, by and between the Company and Softell Inc.
+Added: Consulting Agreement by and between Scienture Holdings, Inc.
+Added: and Draper, Inc.
+Added: dated March 17, 2025 (incorporated by reference to Exhibit 10.1 of the Company’s Form 8-K filed on March 21, 2025).
+Added: Independent Contractor Agreement by and between Scienture Holdings, Inc.
+Added: and EMS Consulting Services, LLC (incorporated by reference to Exhibit 5.1 of the Company’s Form 8-K filed on March 13, 2025).
+Added: Exclusive Commercial and Supply Agreement dated March 4, 2025, by and between Scienture, LLC and Summit Biosciences Inc.
+Added: (incorporated by reference to Exhibit 1.1 of the Company’s Form 8-K filed on March 10, 2025).
Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
12 unchanged sentences
Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
−Removed: Filed herewith.
−Removed: Furnished herewith.
−Removed: # Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5)
−Removed: of Regulation S-K.
−Removed: The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon
−Removed: request by the SEC;
−Removed: provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 under the Exchange
−Removed: Act for any exhibits or schedules so furnished.
+Added: + Indicates management contract or compensatory plan or arrangement.
+Added: Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
+Added: The registrant hereby undertakes to furnish
+Added: supplementally copies of any of the omitted exhibits and schedules upon request by the SEC;
+Added: provided, however, that the registrant may
+Added: request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished.
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
4 unchanged sentences
Executive Officer)
−Removed: November 6, 2024
−Removed: Prashant Patel
Chief Financial Officer
Accounting/Financial Officer)
−Removed: November 6, 2024
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.